Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 23, 2008. The report details a specific corporate action regarding the company's share buyback program authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 250,000 Ordinary shares.
- Purchase Price: 1,200.55 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.08% of total voting rights).
- Shares in Issue: 5,219,680,968 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share count through the cancellation of 250,000 shares purchased on September 23, 2008. This action increased the proportion of Treasury shares held by the company to 9.08% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share ownership notifications.
Investor Verification Checklist
- Verify the total number of shares in issue (5,219,680,968) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (9.08%).
- Note that the 250,000 shares purchased were cancelled, permanently reducing the outstanding share count.